🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses

    Ferring Pharmaceuticals

    Inflammatory Gastrointestinal Disease

    phase 1 other active

    1 trial

  2. A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

    Boehringer Ingelheim

    advanced solid tumors

    phase 1 other active

    1 trial

  3. A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  4. A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

    Boehringer Ingelheim

    unresectable advanced or metastatic solid cancer

    phase 1 other active

    1 trial

  5. A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver

    Boehringer Ingelheim

    No targeted indication. Male and female subjects with obesity.

    phase 1 other active

    1 trial

  6. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  7. A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections, precancers and cancers

    phase 1 other active

    1 trial

  8. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  9. A study to Learn How Safe AGMB-129 is in Healthy Adults Taking Multiple Doses of AGMB-129 That Are Increased a Little at a Time

    Agomab Therapeutics NV

    Fibrostenotic Crohn’s disease

    phase 1 other active

    1 trial

  10. A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participants

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 1 other active

    1 trial

  11. A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

    Centauri Biotech SL

    Bacterial Infection

    phase 1 other active

    1 trial

  12. A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

    GlaxoSmithKline

    Healthy volunteers

    phase 1 other active

    1 trial

  13. A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in mild asthmatics aged 18 to 65 inclusive.

    GlaxoSmithKline

    Mild Asthma

    phase 1 other active

    1 trial

  14. A study to evaluate how well single and multiple doses of O3R-5671-PRO are tolerated in healthy adult subjects

    Lacuna Pharma Pty Ltd

    Inflammatory bowel diseases and psoriasis.

    phase 1 other active

    1 trial

  15. A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmacokinetics) when given as single and repeated doses to healthy participants

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  16. A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).

    Agomab Therapeutics NV

    liver cirrhosis

    phase 1 other active

    1 trial

  17. A study to find a suitable dose of ASP5834 in adults with solid tumors

    Astellas Pharma GmbH

    Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification

    phase 1 other active

    1 trial

  18. A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 other active

    1 trial

  19. A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

    Oncopeptides AB (publ)

    Recurrent glioblastoma

    phase 1 other active

    1 trial

  20. A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants

    Sanofi-aventis Healthcare Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  21. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  22. A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial

  23. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  24. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources